{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:06:04Z","timestamp":1789632364478,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["K142479"],"award-info":[{"award-number":["K142479"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ebr.2026.100876","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:14:01Z","timestamp":1780557241000},"page":"100876","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fenfluramine for seizures in Dravet syndrome and Lennox-Gastaut syndrome: Mechanisms, clinical evidence, safety, and practical integration"],"prefix":"10.1016","volume":"35","author":[{"given":"J\u00f3zsef","family":"Janszky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"J\u00f3zsef","family":"Janszky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9ka","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2026.100876_bb0125","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/epi4.12923","article-title":"Comparative efficacy and safety of first-line add-on therapies for seizures in Dravet syndrome: a network meta-analysis","volume":"9","author":"Guerrini","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2026.100876_bb0040","author":"European Medicines Agency (EMA)"},{"key":"10.1016\/j.ebr.2026.100876_bb0045","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.ebr.2026.100876_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1192022","article-title":"Fenfluramine: a plethora of mechanisms?","volume":"14","author":"Sourbron","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ebr.2026.100876_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.106989","article-title":"Fenfluramine acts as a positive modulator of sigma-1 receptors","volume":"105","author":"Martin","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"16","key":"10.1016\/j.ebr.2026.100876_bb0060","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168416","article-title":"An emerging role for sigma-1 receptors in developmental and epileptic encephalopathies; fenfluramine as a case example","volume":"22","author":"Martin","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"Pt A","key":"10.1016\/j.ebr.2026.100876_bb0030","article-title":"Improved everyday executive functioning after profound seizure reduction with fenfluramine: Dravet syndrome phase 3 open-label extension analysis","volume":"121","author":"Bishop","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2026.100876_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2022.108994","article-title":"Fenfluramine and executive function in preschool Dravet syndrome (<5 years): a critical period","volume":"138","author":"Bishop","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.ebr.2026.100876_bb0065","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0068-15.2015","article-title":"Large-scale phenotype-based antiepileptic drug screening in a zebrafish model of Dravet syndrome","volume":"2","author":"Dinday","year":"2015","journal-title":"eNeuro"},{"issue":"5","key":"10.1016\/j.ebr.2026.100876_bb0070","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/acschemneuro.5b00342","article-title":"Serotonergic modulation as an effective treatment in SCN1A mutant zebrafish","volume":"7","author":"Sourbron","year":"2016","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.ebr.2026.100876_bb0075","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fphar.2017.00191","article-title":"Pharmacological analysis of fenfluramine mechanisms in SCN1A mutant zebrafish","volume":"8","author":"Sourbron","year":"2017","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.ebr.2026.100876_bb0080","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s11064-021-03358-2","article-title":"Efficacy of fenfluramine and norfenfluramine enantiomers in Dravet zebrafish","volume":"46","author":"Li","year":"2021","journal-title":"Neurochem Res"},{"key":"10.1016\/j.ebr.2026.100876_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052522","article-title":"Stereoselective analysis of the antiseizure activity of fenfluramine and norfenfluramine in mice","volume":"25","author":"Erenburg","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ebr.2026.100876_bb0115","article-title":"In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"10216","key":"10.1016\/j.ebr.2026.100876_bb0005","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomized, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ebr.2026.100876_bb0010","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.ebr.2026.100876_bb0020","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/epi.16722","article-title":"Fenfluramine HCl provides long-term clinically meaningful reduction in seizure frequency: open-label extension analysis","volume":"61","author":"Sullivan","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100876_bb0110","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/epi.18241","article-title":"Fenfluramine treatment for Dravet syndrome: long-term real-world analysis demonstrates safety and reduced healthcare burden","volume":"66","author":"Boncristiano","year":"2025","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ebr.2026.100876_bb0015","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.ebr.2026.100876_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17431","article-title":"Fenfluramine provides clinically meaningful reduction in drop seizures in Lennox-Gastaut syndrome: open-label extension interim analysis","volume":"64","author":"Knupp","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2026.100876_bb0135","doi-asserted-by":"crossref","first-page":"110753","DOI":"10.1016\/j.yebeh.2025.110753","article-title":"Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers","volume":"173","author":"Knupp","year":"2025","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2026.100876_bb0140","first-page":"567","article-title":"Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder","volume":"6","author":"Devinsky","year":"2021","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2026.100876_bb0145","series-title":"AES annual meeting 2025; Abstract 2.429","article-title":"Fenfluramine in CDKL5 deficiency disorder: primary efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study","author":"Specchio","year":"2025"},{"issue":"12","key":"10.1016\/j.ebr.2026.100876_bb0085","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/dmcn.14965","article-title":"Fenfluramine for seizures in Sunflower syndrome","volume":"63","author":"Geenen","year":"2021","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ebr.2026.100876_bb0150","article-title":"Fenfluramine treatment improves everyday executive functioning in patients with Lennox-Gastaut syndrome: analysis from a phase 3 clinical trial","author":"Bishop","year":"2021","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ebr.2026.100876_bb0155","series-title":"AES annual meeting","article-title":"Fenfluramine treatment is associated with improvement in everyday executive function in adults with Lennox-Gastaut syndrome: post-hoc analysis of dose effects from a phase 3 trial","author":"Bishop","year":"2022"},{"key":"10.1016\/j.ebr.2026.100876_bb0160","series-title":"AES annual meeting 2025","article-title":"Association of fenfluramine treatment and everyday executive functioning in adult patients with Lennox-Gastaut syndrome","author":"Breuillard","year":"2025"},{"issue":"9","key":"10.1016\/j.ebr.2026.100876_bb0095","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension","volume":"335","author":"Abenhaim","year":"1996","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ebr.2026.100876_bb0100","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ebr.2026.100876_bb0105","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1056\/NEJM199708283370904","article-title":"Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine","volume":"337","author":"Mark","year":"1997","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.ebr.2026.100876_bb0130","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s40265-023-01936-y","article-title":"Pharmacotherapy for Dravet syndrome: a systematic review and network meta-analysis of randomized controlled trials","volume":"83","author":"Lattanzi","year":"2023","journal-title":"Drugs"}],"container-title":["Epilepsy &amp; Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986426000304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986426000304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:48:11Z","timestamp":1789631291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986426000304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S2589986426000304"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2026.100876","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenfluramine for seizures in Dravet syndrome and Lennox-Gastaut syndrome: Mechanisms, clinical evidence, safety, and practical integration","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2026.100876","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100876"}}